Figure 6From: Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis Acceptability curve (incremental cost/LYG). Lifetime decision model (all patients, 3% discounting, 20-year time horizon). LYG = life-years gained.Back to article page